SynthesisFrontiers in oncology2021

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials.

Zaishang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.